• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

干性年龄相关性黄斑变性的全球负担:一项针对性文献综述

Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review.

作者信息

Schultz Neil M, Bhardwaj Shweta, Barclay Claudia, Gaspar Luis, Schwartz Jason

机构信息

Astellas Pharma Inc, Northbrook, Illinois.

IQVIA, London, United Kingdom.

出版信息

Clin Ther. 2021 Oct;43(10):1792-1818. doi: 10.1016/j.clinthera.2021.08.011. Epub 2021 Sep 20.

DOI:10.1016/j.clinthera.2021.08.011
PMID:34548176
Abstract

PURPOSE

Age-related macular degeneration (AMD) is a leading cause of blindness, particularly in higher-income countries. Although dry AMD accounts for 85% to 90% of AMD cases, a comprehensive understanding of the global dry AMD burden is needed.

METHODS

A targeted literature review was conducted in PubMed, MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (1995-2019) to identify data on the epidemiology, management, and humanistic and economic burden of dry AMD in adults. A landscape analysis of patient-reported outcome (PRO) instruments in AMD was also conducted via searches in PubMed (1995-2019), ClinicalTrials.gov, PROQOLID, PROLABELS, and health technology assessment reports (2008-2018).

FINDINGS

Thirty-seven of 4205 identified publications were included in the review. Dry AMD prevalence was 0.44% globally, varied across ethnic groups, and increased with age. Patients with dry AMD had higher risks of all-cause mortality (hazard ratio [HR] = 1.46; 95% CI, 0.99-2.16) and tobacco-related (HR = 2.86; 95% CI, 1.15-7.09) or cancer deaths (HR = 3.37; 95% CI, 1.56-7.29; P = 0.002) than those without dry AMD. Smoking, increasing age or cholesterol levels, and obesity are key risk factors for developing dry AMD. No treatment guidelines were identified for dry AMD specifically; management focuses on risk factor reduction and use of dietary supplements. In the United States and Italy, direct medical costs and health care resource utilization were lower in patients with dry versus wet AMD. Patients with dry AMD, particularly advanced disease, experienced significant visual function impairment. Dry AMD symptoms included reduced central vision, decreased ability to see at night, increased visual blurriness, distortion of straight lines and text, and faded color vision. Most PRO instruments used in AMD evaluations covered few, if any, of the identified symptoms reported by patients with dry AMD. Although the Quality of Life and Vision Function Questionnaire, 25-item National Eye Institute Vision Function Questionnaire, Low Vision Quality of Life, Impact of Vision Impairment-Very Low Vision, and Functional Reading Independence Index had strong content validity and psychometric properties in patients with dry AMD, they retained limited coverage of salient concepts.

IMPLICATIONS

Despite dry AMD accounting for most AMD cases, there are substantial gaps in the published literature, particularly the humanistic and economic burden of disease and the lack of differentiation among dry, wet, or unspecified dry AMD. The significant burden of illness alludes to a high unmet need for tolerable and effective treatment options, as well as PRO instruments with more coverage of dry AMD symptoms and salient concepts.

摘要

目的

年龄相关性黄斑变性(AMD)是导致失明的主要原因,在高收入国家尤为如此。尽管干性AMD占AMD病例的85%至90%,但仍需要对全球干性AMD负担有全面的了解。

方法

在PubMed、MEDLINE、Embase和Cochrane系统评价数据库(1995 - 2019年)中进行有针对性的文献综述,以确定关于成人干性AMD的流行病学、管理以及人文和经济负担的数据。还通过在PubMed(1995 - 2019年)、ClinicalTrials.gov、PROQOLID、PROLABELS和卫生技术评估报告(2008 - 2018年)中检索,对AMD患者报告结局(PRO)工具进行了全景分析。

结果

在4205篇已识别的出版物中,有37篇被纳入综述。全球干性AMD患病率为0.44%,因种族而异,并随年龄增长而增加。与没有干性AMD的患者相比,干性AMD患者全因死亡风险更高(风险比[HR]=1.46;95%置信区间,0.99 - 2.16),与烟草相关的死亡风险(HR = 2.86;95%置信区间,1.15 - 7.09)或癌症死亡风险(HR = 3.37;95%置信区间,1.56 - 7.29;P = 0.002)更高。吸烟、年龄增长、胆固醇水平升高和肥胖是发生干性AMD的关键危险因素。未发现专门针对干性AMD的治疗指南;管理重点在于降低危险因素和使用膳食补充剂。在美国和意大利,干性AMD患者的直接医疗费用和卫生保健资源利用率低于湿性AMD患者。干性AMD患者,尤其是晚期疾病患者,存在明显的视觉功能损害。干性AMD症状包括中心视力下降、夜间视力下降、视物模糊增加、直线和文字变形以及色觉减退。AMD评估中使用的大多数PRO工具几乎未涵盖干性AMD患者报告的已识别症状。尽管生活质量与视觉功能问卷、25项国家眼科研究所视觉功能问卷、低视力生活质量、视力损害影响 - 极低视力和功能性阅读独立性指数在干性AMD患者中具有较强的内容效度和心理测量特性,但它们对显著概念的覆盖范围仍然有限。

启示

尽管干性AMD占大多数AMD病例,但已发表的文献存在重大差距,特别是疾病的人文和经济负担以及干性、湿性或未明确的干性AMD之间缺乏区分。疾病的重大负担表明对可耐受且有效的治疗选择以及能更多覆盖干性AMD症状和显著概念的PRO工具存在高度未满足的需求。

相似文献

1
Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review.干性年龄相关性黄斑变性的全球负担:一项针对性文献综述
Clin Ther. 2021 Oct;43(10):1792-1818. doi: 10.1016/j.clinthera.2021.08.011. Epub 2021 Sep 20.
2
Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review.干性年龄相关性黄斑变性和 Stargardt 病的治疗方法:系统评价。
Health Technol Assess. 2018 May;22(27):1-168. doi: 10.3310/hta22270.
3
Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.双侧新生血管性年龄相关性黄斑变性的经济负担:多国观察性研究。
Pharmacoeconomics. 2008;26(1):57-73. doi: 10.2165/00019053-200826010-00006.
4
Age related macular degeneration and visual disability.年龄相关性黄斑变性与视力障碍。
Curr Drug Targets. 2011 Feb;12(2):221-33. doi: 10.2174/138945011794182755.
5
[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].[德国的新生血管性年龄相关性黄斑变性。对生活质量的影响及经济负担]
Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9.
6
Comparison of vision-related quality of life in primary open-angle glaucoma and dry-type age-related macular degeneration.原发性开角型青光眼与干性年龄相关性黄斑变性患者视觉相关生活质量的比较。
Eye (Lond). 2017 Mar;31(3):395-405. doi: 10.1038/eye.2016.219. Epub 2016 Nov 4.
7
[Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].[法国新生血管性年龄相关性黄斑变性患者的人文负担与卫生资源利用情况]
J Fr Ophtalmol. 2008 Feb;31(2):138-45. doi: 10.1016/s0181-5512(08)70346-2.
8
Burden of illness of neovascular age-related macular degeneration in Canada.加拿大新生血管性年龄相关性黄斑变性的疾病负担。
Can J Ophthalmol. 2007 Dec;42(6):836-43. doi: 10.3129/i07-153.
9
Statins for age-related macular degeneration.用于年龄相关性黄斑变性的他汀类药物。
Cochrane Database Syst Rev. 2016 Aug 4;2016(8):CD006927. doi: 10.1002/14651858.CD006927.pub5.
10
Metamorphopsia and vision-related quality of life among patients with age-related macular degeneration.年龄相关性黄斑变性患者的形觉扭曲和与视觉相关的生活质量。
Can J Ophthalmol. 2018 Apr;53(2):168-172. doi: 10.1016/j.jcjo.2017.08.006. Epub 2017 Oct 25.

引用本文的文献

1
Impact of Donor and Host Age on Systemic Cell Therapy to Treat Age-Related Macular Degeneration.供体和宿主年龄对全身细胞治疗年龄相关性黄斑变性的影响。
Cells. 2025 Sep 1;14(17):1360. doi: 10.3390/cells14171360.
2
ODDM: Integration of SMOTE Tomek with Deep Learning on Imbalanced Color Fundus Images for Classification of Several Ocular Diseases.ODDM:在不平衡的彩色眼底图像上集成SMOTE Tomek与深度学习以对多种眼部疾病进行分类
J Imaging. 2025 Aug 18;11(8):278. doi: 10.3390/jimaging11080278.
3
Epigenetic Alterations in Age-Related Macular Degeneration: Mechanisms and Implications.
年龄相关性黄斑变性中的表观遗传改变:机制与意义
Int J Mol Sci. 2025 Aug 6;26(15):7601. doi: 10.3390/ijms26157601.
4
Potential Therapeutic Actions of Flavonoids Present in Propolis That Modulate Vascular Endothelial Growth Factor Signaling to Regulate Angiogenesis.蜂胶中存在的类黄酮调节血管内皮生长因子信号传导以调控血管生成的潜在治疗作用。
Phytother Res. 2025 Sep;39(9):4230-4246. doi: 10.1002/ptr.70029. Epub 2025 Aug 9.
5
Diabetes-Driven Retinal Neurodegeneration: Its Role in the Pathogenesis of Diabetic Retinopathy.糖尿病驱动的视网膜神经退行性变:其在糖尿病视网膜病变发病机制中的作用。
Biomedicines. 2025 May 29;13(6):1328. doi: 10.3390/biomedicines13061328.
6
Bruch's membrane heparan sulfate retains lipoproteins in the early stages of age-related macular degeneration.布鲁赫膜硫酸乙酰肝素在年龄相关性黄斑变性的早期阶段保留脂蛋白。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2500727122. doi: 10.1073/pnas.2500727122. Epub 2025 Jun 13.
7
Determinants of Healthcare Professionals' Knowledge on Age-Related Macular Degeneration Risk Factors in Ethiopia.埃塞俄比亚医疗保健专业人员对年龄相关性黄斑变性风险因素的认知决定因素
Clin Ophthalmol. 2025 Jun 4;19:1771-1785. doi: 10.2147/OPTH.S514480. eCollection 2025.
8
Gene therapy strategies in ophthalmology-an overview of current developments and future prospects.眼科中的基因治疗策略——当前进展与未来前景综述
J Appl Genet. 2025 Jun 5. doi: 10.1007/s13353-025-00973-5.
9
Clinical characterization of CCT2 and its role in autophagy regulation during age-related macular degeneration.CCT2的临床特征及其在年龄相关性黄斑变性自噬调节中的作用。
Sci Rep. 2025 May 15;15(1):16849. doi: 10.1038/s41598-025-01907-1.
10
Predictive factors for adherence to intravitreal anti-vascular endothelial growth factor therapy in Palestinian patients with diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration: a retrospective cohort study.巴勒斯坦糖尿病视网膜病变、视网膜静脉阻塞和年龄相关性黄斑变性患者玻璃体内抗血管内皮生长因子治疗依从性的预测因素:一项回顾性队列研究。
BMC Ophthalmol. 2025 May 6;25(1):268. doi: 10.1186/s12886-025-04113-9.